19 · Industry

MedTech & Medical Devices

MedTech & Medical Devices brings legal and Financial Crime exposure into the same operating environment as device development, quality, clinical evidence, distributors, procurement, cybersecurity and post-market surveillance. For your organisation, the key question is whether MedTech Governance, Three Lines Integration & Executive Accountability, Product Integrity, Quality, Safety & Evidentiary Governance, and Hospital Procurement, Tenders, Discounts & Commercial Integrity are connected early enough to identify material exposure before it becomes a regulatory, criminal, operational or reputational event.

FACTCONTEXTRISKNORMCONTROLDECISIONEVIDENCEASSURANCEREMEDIATIONLEARNING
Legal-strategic perspective

MedTech & Medical Devices brings legal and Financial Crime exposure into the same operating environment as device development, quality, clinical evidence, distributors, procurement, cybersecurity and post-market surveillance. For your organisation, the key question is whether MedTech Governance, Three Lines Integration & Executive Accountability, Product Integrity, Quality, Safety & Evidentiary Governance, and Hospital Procurement, Tenders, Discounts & Commercial Integrity are connected early enough to identify material exposure before it becomes a regulatory, criminal, operational or reputational event. The control architecture must also account for Distributors, Resellers, Agents & Third-Party Risk, Anti-Bribery, HCP Interactions, Consulting & Conflicts of Interest, and Reimbursement, Claims, Pricing & Healthcare Fraud Risk, while Connected Devices, Cybersecurity, Software & Digital Resilience, Sanctions, Export Controls, Supply Chains & Market Access, Product Investigations, Regulatory Enforcement, Recovery & Litigation, and Continuous Assurance, Remediation & MedTech Transformation determine whether decisions remain supported by reliable data, evidence, escalation and assurance. Van Leeuwen Law Firm approaches MedTech & Medical Devices through an integrated legal, forensic and governance lens so that sector-specific risk is translated into clear ownership, proportionate controls and defensible executive decisions.

The ten substantive anchors on this page are treated as connected parts of one governance and risk problem. For this industry, the objective is to connect legal analysis, facts, data, ownership, decision rights, controls and evidence so that material exposure can be recognised early, challenged independently and translated into action that remains defensible under later scrutiny.

10

10 key subthemes

These ten themes are the substantive anchors for legal analysis, governance, decision-making, execution and assurance.

  1. 01MedTech Governance, Three Lines Integration & Executive Accountability
  2. 02Product Integrity, Quality, Safety & Evidentiary Governance
  3. 03Hospital Procurement, Tenders, Discounts & Commercial Integrity
  4. 04Distributors, Resellers, Agents & Third-Party Risk
  5. 05Anti-Bribery, HCP Interactions, Consulting & Conflicts of Interest
  6. 06Reimbursement, Claims, Pricing & Healthcare Fraud Risk
  7. 07Connected Devices, Cybersecurity, Software & Digital Resilience
  8. 08Sanctions, Export Controls, Supply Chains & Market Access
  9. 09Product Investigations, Regulatory Enforcement, Recovery & Litigation
  10. 10Continuous Assurance, Remediation & MedTech Transformation
Strategic depth

From substantive anchors to governable choices

The four blocks below connect the ten page-specific subthemes with materiality, decision-making, governance, execution and the evidential position your organisation may later need to defend.

01

Integrated Financial Crime Risk Management

MedTech Governance, Three Lines Integration & Executive AccountabilityProduct Integrity, Quality, Safety & Evidentiary GovernanceHospital Procurement, Tenders, Discounts & Commercial Integrity

Within MedTech & Medical Devices, Integrated Financial Crime Risk Management is not a separate compliance layer. It is the discipline of connecting legal, operational and integrity exposure through one coherent factual and risk picture. The substantive anchors in this block are MedTech Governance, Three Lines Integration & Executive Accountability, Product Integrity, Quality, Safety & Evidentiary Governance, and Hospital Procurement, Tenders, Discounts & Commercial Integrity. For MedTech Governance, Three Lines Integration & Executive Accountability, ownership, independent challenge, decision rights, escalation and management information must be designed so that responsibility remains clear and material decisions can later be reconstructed from reliable evidence. For Product Integrity, Quality, Safety & Evidentiary Governance, ownership, independent challenge, decision rights, escalation and management information must be designed so that responsibility remains clear and material decisions can later be reconstructed from reliable evidence. For Hospital Procurement, Tenders, Discounts & Commercial Integrity, the issue must be translated into verifiable facts, explicit ownership, materiality criteria, proportionate controls, clear escalation and evidence capable of supporting later review.

For this industry, this means signals from the business, Legal, Compliance, Finance, Data, Technology and investigations should not remain separated when they relate to the same customer, transaction, third party, event or decision. Control quality is therefore assessed by whether material exposure is recognised in time, ownership is clear and decisions are supported by sufficient facts and evidence—not by the number of isolated controls in place.

02

Governance, Three Lines and decision-making

Distributors, Resellers, Agents & Third-Party RiskAnti-Bribery, HCP Interactions, Consulting & Conflicts of InterestReimbursement, Claims, Pricing & Healthcare Fraud Risk

Governance within MedTech & Medical Devices becomes effective only when formal responsibility is visible in actual decision-making. The anchors Distributors, Resellers, Agents & Third-Party Risk, Anti-Bribery, HCP Interactions, Consulting & Conflicts of Interest, and Reimbursement, Claims, Pricing & Healthcare Fraud Risk determine how First Line ownership, independent Second Line challenge and Third Line assurance can operate from a common factual base without losing role clarity. For Distributors, Resellers, Agents & Third-Party Risk, selection, due diligence, contractual safeguards, ownership, actual performance, payment flows, monitoring and exit options must remain connected throughout the relationship with third parties. For Anti-Bribery, HCP Interactions, Consulting & Conflicts of Interest, behavioural, identity, payment and network indicators must be combined early enough to protect assets and victims, while investigation, blocking, reporting and recovery decisions remain legally controlled and evidentially traceable. For Reimbursement, Claims, Pricing & Healthcare Fraud Risk, behavioural, identity, payment and network indicators must be combined early enough to protect assets and victims, while investigation, blocking, reporting and recovery decisions remain legally controlled and evidentially traceable.

Van Leeuwen Law Firm translates this into decision rights, escalation criteria, management information, exception governance and a traceable record of executive judgement. The result is not a paper Three Lines model, but a governance cycle in which information moves between the lines, challenge is demonstrable and residual risk is explicitly accepted, reduced or terminated.

03

Strategic direction and enterprise-wide embedding

Connected Devices, Cybersecurity, Software & Digital ResilienceSanctions, Export Controls, Supply Chains & Market Access

The strategic value of MedTech & Medical Devices arises when Connected Devices, Cybersecurity, Software & Digital Resilience and Sanctions, Export Controls, Supply Chains & Market Access are directly connected to enterprise choices, investment priorities, capacity and the operating model. For Connected Devices, Cybersecurity, Software & Digital Resilience, data quality, lineage, access control, model and cyber risk, explainability, logging and digital evidence integrity determine both operational effectiveness and the defensibility of later decisions. For Sanctions, Export Controls, Supply Chains & Market Access, sanctions regimes, ownership and control, indirect exposure, circumvention indicators, geographic context, end-use and escalation thresholds must be brought together in one auditable factual picture.

That requires an explicit relationship between risk appetite, legal constraints, commercial or institutional objectives and the resources needed for controls to operate in practice. Van Leeuwen Law Firm therefore focuses on which option is legally executable and institutionally defensible, which residual risk remains and which evidence is needed to sustain the chosen course under regulatory review, investigation or dispute.

04

Integrity steering in a structurally changing risk landscape

Product Investigations, Regulatory Enforcement, Recovery & LitigationContinuous Assurance, Remediation & MedTech Transformation

The control environment around MedTech & Medical Devices must remain adaptive because Product Investigations, Regulatory Enforcement, Recovery & Litigation and Continuous Assurance, Remediation & MedTech Transformation are continuously affected by technological change, cyber threats, geopolitics, sanctions, evolving data, regulatory change and third-party dependencies. For Product Investigations, Regulatory Enforcement, Recovery & Litigation, scope, independence, privilege, preservation, chain of custody, interviews, documentation and evidential assessment are central to moving from allegation to a reliable factual record and a defensible enforcement or litigation position. For Continuous Assurance, Remediation & MedTech Transformation, the focus moves from identifying deficiencies to root-cause analysis, demonstrable remediation, independent validation, sustainable embedding and management information on residual risk and effectiveness.

Effective integrity steering therefore requires continuous sensing, periodic recalibration of scenarios, integration of incidents and investigation findings into risk models, and timely adjustment of governance and controls. Change is then not processed only after an incident; it is systematically translated into revised assumptions, decision thresholds, controls, training, assurance and board-level information.

Your next step

Discuss your matter

Van Leeuwen Law Firm connects legal analysis, facts, evidence, governance and strategic execution around your specific matter.

Facts and evidenceExecutive decision spaceExecutable next steps
Contact Van Leeuwen Law Firm →

← Back to overview